the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-01

Study Completion Date

2022-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the Safety and Efficacy of Exosomes Derived from Allogenic Adipose Mesenchymal Stem Cells（MSCs-Exos）in Subjects with Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

NCT02833792

Alzheimer Dementia

UNKNOWN PHASE2

Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

NCT04855955

Alzheimer Disease

NO_LONGER_AVAILABLE

Alzheimer's Disease Stem Cells Multiple Infusions

NCT04040348

Alzheimer Disease

COMPLETED PHASE1

Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease

NCT04482413

Alzheimer Disease

UNKNOWN PHASE2

Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease

NCT01547689

Alzheimer's Disease

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, the main pathological characteristics of AD patients are the accumulation of β-amyloid (Aβ) into senile plaques, the abnormal aggregation of intracellular Tau protein to form neuron fiber tangles (NFT) and neuron death. There are still no effective treatments to prevent, halt, or reverse Alzheimer's disease.

Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers with the abundance of adhesive proteins that readily interact with cellular membranes. These vesicles have a content that includes cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. Exosomes are involved in cell-to-cell communication, cell signaling, and altering cell or tissue metabolism at short or long distances in the body, and can influence tissue responses to injury, infection, and disease.

The purpose of this single center, open label, phase I/Ⅱ clinical trial, therefore, is to explore the safety and efficacy of the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exos) in the treatment of mild to moderate dementia due to Alzheimer's Disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MSCs-Exos Dosage 1

MSCs-Exos. low-dose group

Group Type EXPERIMENTAL

low dosage MSCs-Exos administrated for nasal drip

Intervention Type BIOLOGICAL

Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

MSCs-Exos Dosage 2

MSCs-Exos mid-dose group

Group Type EXPERIMENTAL

mild dosage MSCs-Exos administrated for nasal drip

Intervention Type BIOLOGICAL

Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

MSCs-Exos Dosage 3

MSCs-Exos high-dose group

Group Type EXPERIMENTAL

high dosage MSCs-Exos administrated for nasal drip

Intervention Type BIOLOGICAL

Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

low dosage MSCs-Exos administrated for nasal drip

Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

Intervention Type BIOLOGICAL

mild dosage MSCs-Exos administrated for nasal drip

Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

Intervention Type BIOLOGICAL

high dosage MSCs-Exos administrated for nasal drip

Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects themselves and their legal representatives (or their immediate family members) voluntarily received the treatment and signed the consent form before this study;
2. Age ≧ 50 years, males and females;
3. Subjects diagnosed with Patients with mild or moderate Alzheimer's disease, based on the NIA/AA(2011).
4. The Mini-Mental Status Examination (MMSE) score was 10-24 (inclusive);
5. Modified Hachinski Ischemic Scale (MHIS) score was ≦ 4;
6. Suspension of cognitive-enhancing drugs and marketed therapeutic drugs such as ginkgo, high-dose vitamin E, lecithin, estrogen, non-steroidal anti-inflammatory drugs (NSAIDs), Donepezil, Memantine, etc ;
7. Based on medical history, physical examination, vital signs, laboratory tests and 12-lead electrocardiogram (ECG) results, subjects are generally in good condition;
8. Subjects can walk independently or receive outpatient follow-up with assistive devices (wheelchairs, walkers or crutches), while the subject's vision and hearing (allowing glasses and / or hearing aids) do not affect the follow-up procedure;
9. The subject has an identified and reliable caregiver who must also meet the following conditions:

(1) In the hospital, caregiver can independently read and understand relevant research documents, and can do necessary communication with the investigator; (2) Caregiver can follow clinical research procedures and ensure that accurate information about the status of the subject can be provided during the study; (3) Caregiver live with the subject; or take care of the subject no less than 3 days a week and no less than 2 hours a day; 10. Female subjects with fertility (including women of childbearing age and women less than 1 year after menopause) were required to take effective contraception throughout the study. At the same time, urine pregnancy tests were negative during screening.

Exclusion Criteria

1. The subjects with more serious allergic constitution;
2. Received allogeneic mesenchymal progenitor cell therapy or its derived exosomes;
3. Laboratory test (any item meets): neutrophil absolute number \< 1.0 × 109 / L, platelet count \< 100 × 109 / L, serum albumin \< 30g / L, serum creatinine \> upper limit of normal value range, total bilirubin, alanine aminotransferase, aspartate aminotransferase \> upper limit of 2 times of normal value range;
4. The subject has serious and poorly controlled concomitant diseases, such as (but not limited to) cardiovascular, cerebrovascular, liver, kidney, lung, endocrine and other system diseases;
5. Severe Alzheimer's Disease;
6. Severe depression;
7. The subjects suffered from Parkinson's disease, multiple cerebral infarction, vascular dementia, Huntington's disease, hydrocephalus, progressive supranuclear paralysis, multiple sclerosis, epilepsy, mental retardation or major history of brain injury (with or without persistent neurological impairment) or known brain structural abnormalities;
8. The subject has an history malignant tumor；
9. The subject has severe generalized infectious diseases in the 3 months prior to this trial.;
10. The subject has contraindication of MRI, included but not only: the subject installed heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip after aneurysm surgery, drug infusion device implanted in vivo, any electronic device implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil, strainer, ECG monitor, metal suture, shrapnel or sand of body, plate fixation and steel nail after fracture surgery, artificial cochlea, middle ear shift plant, metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill patient and so on.
11. The subject tests positive for: HIV, HBV, HCV and treponema pallidum;
12. The subject has history of alcoholism, drug abuse, or mental illness in the 10 years prior to this trial.
13. The subject has participated in any other clinical trial in the 6 months prior to this trial;
14. The female subjects are pregnant, lactating or pregnant in the past half a year;
15. The subject has any other unsuitable condition (such as factors reducing the follow-up compliance) to be determined by the investigator.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No